{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:54:07Z","timestamp":1777100047436,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2021R1G1A101383912"],"award-info":[{"award-number":["2021R1G1A101383912"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00277-023-05411-2","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:08:05Z","timestamp":1692587285000},"page":"3167-3175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP"],"prefix":"10.1007","volume":"102","author":[{"given":"Moonho","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchel","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heui-June","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk-Hun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Suk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Seok","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong-Sub","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-6205","authenticated-orcid":false,"given":"Sang-Wook","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"issue":"4","key":"5411_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12185-018-2403-9","volume":"107","author":"KH Yoo","year":"2018","unstructured":"Yoo KH, Lee H, Suh C, CISL. (2018) Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial. Int J Hematol 107(4):395\u2013404","journal-title":"Int J Hematol"},{"issue":"1","key":"5411_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4143\/crt.2017.093","volume":"50","author":"H Lee","year":"2018","unstructured":"Lee H, Park HJ, Park EH, Ju HY, Oh CM, Kong HJ, Jung KW et al (2018) Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat 50(1):222\u2013238","journal-title":"Cancer Res Treat"},{"issue":"4","key":"5411_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"10216","key":"5411_CR4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P et al (2019) Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 394(10216):2271\u20132281","journal-title":"Lancet"},{"issue":"9","key":"5411_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842\u2013858","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"5411_CR6","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248\u2013v251","journal-title":"Ann Oncol"},{"issue":"10","key":"5411_CR7","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266","journal-title":"Cancer"},{"issue":"21","key":"5411_CR8","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167","journal-title":"J Clin Oncol"},{"issue":"1","key":"5411_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"11","key":"5411_CR10","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/cncr.11827","volume":"98","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98(11):2402\u20132409","journal-title":"Cancer"},{"issue":"28","key":"5411_CR11","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"3","key":"5411_CR12","first-page":"799","volume":"46","author":"S Cheol Seong","year":"2017","unstructured":"Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, Do CH et al (2017) Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol 46(3):799\u2013800","journal-title":"Int J Epidemiol"},{"issue":"6","key":"5411_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s12185-021-03118-6","volume":"113","author":"M Ise","year":"2021","unstructured":"Ise M, Matsuda K, Shimura A, Masamoto Y, Kurokawa M (2021) Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients. Int J Hematol 113(6):823\u2013831","journal-title":"Int J Hematol"},{"issue":"8","key":"5411_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jiac.2021.03.004","volume":"27","author":"K Matsuda","year":"2021","unstructured":"Matsuda K, Jo T, Miyauchi M, Toyama K, Nakazaki K, Matsui H, Fushimi K et al (2021) Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: a nationwide analysis in Japan. J Infect Chemother 27(8):1151\u20131155","journal-title":"J Infect Chemother"},{"issue":"12","key":"5411_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12(12):1416\u20131424","journal-title":"Oncologist"},{"issue":"4","key":"5411_CR16","first-page":"Cd003189","volume":"2008","author":"J Bohlius","year":"2008","unstructured":"Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008(4):Cd003189","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"5411_CR17","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1080\/10428194.2020.1791846","volume":"61","author":"D Straus","year":"2020","unstructured":"Straus D, Collins G, Walewski J, Zinzani PL, Grigg A, Sureda A, Illes A et al (2020) Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III\/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma 61(12):2931\u20132938","journal-title":"Leuk Lymphoma"},{"key":"5411_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4419-7073-2_8","volume":"157","author":"NM Kuderer","year":"2011","unstructured":"Kuderer NM (2011) Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy. Cancer Treat Res 157:127\u2013143","journal-title":"Cancer Treat Res"},{"issue":"7","key":"5411_CR19","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/annonc\/mdv174","volume":"26","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Reiner M, Morrow PK, Crawford J (2015) The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol 26(7):1452\u20131458","journal-title":"Ann Oncol"},{"issue":"6","key":"5411_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","volume":"147","author":"L Sung","year":"2007","unstructured":"Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147(6):400\u2013411","journal-title":"Ann Intern Med"},{"issue":"2","key":"5411_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clcc.2016.08.008","volume":"16","author":"T Pinter","year":"2017","unstructured":"Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y et al (2017) A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX\/bevacizumab or FOLFIRI\/bevacizumab for locally advanced or metastatic colorectal cancer: final results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clin Colorectal Cancer 16(2):103\u2013114.e103","journal-title":"Clin Colorectal Cancer"},{"issue":"16","key":"5411_CR22","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1200\/JCO.2003.01.076","volume":"21","author":"JK Doorduijn","year":"2003","unstructured":"Doorduijn JK, Van Der Holt B, Van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ et al (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 21(16):3041\u20133050","journal-title":"J Clin Oncol"},{"issue":"3","key":"5411_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00520-016-3468-8","volume":"25","author":"C Cerchione","year":"2017","unstructured":"Cerchione C, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Pane F et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer 25(3):839\u2013845","journal-title":"Support Care Cancer"},{"issue":"6","key":"5411_CR24","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00520-019-05080-w","volume":"28","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Guo H, Gawade PL, Kim C, Bensink ME, Chandler D (2020) Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015. Support Care Cancer 28(6):2637\u20132649","journal-title":"Support Care Cancer"},{"issue":"15","key":"5411_CR25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/jnci\/djt182","volume":"105","author":"N Lathia","year":"2013","unstructured":"Lathia N, Isogai PK, Angelis CD, Smith TJ, Cheung M, Mittmann N, Hoch JS et al (2013) Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst 105(15):1078\u20131085","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"5411_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jval.2010.10.037","volume":"14","author":"S Whyte","year":"2011","unstructured":"Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health 14(4):465\u2013474","journal-title":"Value Health"},{"issue":"6","key":"5411_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2165\/11590130-000000000-00000","volume":"30","author":"BR Hirsch","year":"2012","unstructured":"Hirsch BR, Lyman GH (2012) Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics 30(6):497\u2013511","journal-title":"Pharmacoeconomics"},{"issue":"34","key":"5411_CR28","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/JCO.2012.48.3644","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ et al (2013) Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 31(34):4283\u20134289","journal-title":"J Clin Oncol"},{"issue":"3","key":"5411_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-016-3954-1","volume":"159","author":"T Younis","year":"2016","unstructured":"Younis T, Rayson D, Jovanovic S, Skedgel C (2016) Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review. Breast Cancer Res Treat 159(3):425\u2013432","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"5411_CR30","first-page":"450","volume":"76","author":"T Ichimura","year":"2021","unstructured":"Ichimura T, Nomura H, Shimizu H, Machida Y, Suzuki K (2021) Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer. Pharmazie 76(9):450\u2013454","journal-title":"Pharmazie"},{"issue":"10","key":"5411_CR31","first-page":"e2217","volume":"2022","author":"P Cornes","year":"2022","unstructured":"Cornes P, Kelton J, Liu R, Zaidi O, Stephens J, Yang J (2022) Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate\/high risk of febrile neutropenia. Future Oncol 2022(10):e2217","journal-title":"Future Oncol"},{"issue":"2","key":"5411_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jep.12597","volume":"23","author":"TJ Wen","year":"2017","unstructured":"Wen TJ, Wen YW, Chien CR, Chiang SC, Hsu WW, Shen LJ, Hsiao FY (2017) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin\u2019s lymphoma patients under Taiwan's national health insurance system. J Eval Clin Pract 23(2):288\u2013293","journal-title":"J Eval Clin Pract"},{"issue":"8","key":"5411_CR33","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1200\/OP.20.01047","volume":"17","author":"E Li","year":"2021","unstructured":"Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH (2021) Primary prophylaxis with biosimilar Filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis. JCO Oncol Pract 17(8):e1235\u2013e1245","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"5411_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40273-016-0474-0","volume":"35","author":"K Fust","year":"2017","unstructured":"Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC et al (2017) cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma. Pharmacoeconomics 35(4):425\u2013438","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"5411_CR35","doi-asserted-by":"publisher","first-page":"e0148901","DOI":"10.1371\/journal.pone.0148901","volume":"11","author":"XJ Wang","year":"2016","unstructured":"Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL et al (2016) Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (Nivestim) or Pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PLoS One 11(2):e0148901","journal-title":"PLoS One"},{"issue":"1","key":"5411_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-015-3309-3","volume":"150","author":"EK Lee","year":"2015","unstructured":"Lee EK, Wong WW, Trudeau ME, Chan KK (2015) Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat 150(1):169\u2013180","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5411_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3111\/13696998.2013.844160","volume":"17","author":"G Hill","year":"2014","unstructured":"Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH (2014) Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin\u2019s lymphoma: cost-effectiveness analyses. J Med Econ 17(1):32\u201342","journal-title":"J Med Econ"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05411-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:03:27Z","timestamp":1697058207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05411-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5411"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05411-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived because this study used anonymized data from the NHIS, adhering to a stringent confidentiality protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}